Categories
Global Equities
Rob Lovelace on the year ahead
Rob Lovelace
Equity Portfolio Manager and Chair, Capital International, Inc.
MARKETING LAB

Share this article and more with your clients

Our easy-to-use tool lets you personalize and share our thought leadership with your branding via email, social media or PDF.

Investing in the pandemic era has raised a whole new set of challenges. But in some ways, the fundamentals haven’t changed. Corporate earnings still matter.


In fact, they might just matter more than ever, as Capital Group vice chair and president Rob Lovelace asserts in this wide-ranging Q&A. The bull market may be long in the tooth and overdue for a correction, he explains, but there’s a reason the pandemic couldn’t bring it down.


What’s your outlook for global equity markets as we embark on a new year?


There’s a three-part framework I like to use and that is: pandemic, economy, markets. The pandemic is going to be with us for a while, but it will have a diminishing impact on the economy over time. That’s the pattern we’ve seen. And the health of the economy matters a lot to the bond market, but less so to the equity markets. The stock market is driven by the earnings of the companies that are listed, and many companies have done well even during the COVID period. So we should see the pandemic having less impact on the economy, the economy continuing to expand and companies well positioned to thrive.


After the COVID correction in the first quarter of 2020, stocks not only bounced back, they continued the extension of what we now realize is a decade-long bull market. It's been led by the same group of U.S. tech-related stocks that we used to call the FAANGs — Facebook (now Meta), Amazon, Apple, Netflix and Google (now Alphabet), along with Microsoft, and I think Tesla has joined the group. That long-term trend is still in place. COVID interrupted the climb, but it didn’t change the fundamental direction of the markets.


Pandemic-era rally is a continuation of a long bull market

The chart is a line that illustrates the rise of the Standard & Poor’s 500 Composite Index from 2010 to 2021, and which type of stocks led during various periods. A group of growth stocks consisting of Microsoft, Tesla, Meta (Facebook), Amazon, Apple, Netflix and Alphabet (Google) led most of the way, interrupted only by short periods when cyclical or defensive stocks led the way.

Sources: Capital Group, FactSet, MSCI, Standard & Poor’s. As of 12/31/21. MT FAANG represents the collective price performance of shares of Microsoft, Tesla, Meta (Facebook), Amazon, Apple, Netflix and Alphabet (Google).

Over this 10-year period, we’ve definitely seen some excesses building up, and it’s usually these excesses that need to be cleaned out by a correction. That doesn’t mean it’s going to happen right away but, at some point a stabilization in prices, if not a full correction, would probably be a good thing at this point in the cycle. We may be seeing that needed correction starting already this year.


As a global investor, what are your thoughts on the world’s major economies?


I’m expecting solid economic growth in the U.S. and Europe. It may be slower in China, but as I mentioned earlier, economies are not necessarily the best indicators of stock market levels. Equity markets will do well depending on the performance of the underlying companies. The key driver is corporate earnings growth.


Let’s take a look at the U.S. stock market, which has been compounding at more than 16% a year over the past 10 years. That’s a remarkable number. Many people think it’s because of the stimulus that has come into the market, so most of it has been due to multiple expansion. But that's only half the reason. The compound average growth rate of U.S. corporate earnings has been over 7% a year. So that means about half the growth is driven by earnings and the other half is driven by investors valuing those earnings more highly.


This chart (shown below) makes a powerful statement about what's happened over the past decade in the U.S. compared to other major equity markets.


Strong earnings and P/E growth push U.S. markets higher

The bar chart represents annualized total returns, earnings growth and valuation expansion for stock markets in the U.S., Europe, Japan, emerging markets and China over the past 10 years as of December 31, 2021. The U.S. return was 16.5% while earnings growth was 7.2% and valuation expansion was 6.6%. Europe’s return was 8.5% while earnings growth was 0.1% and valuation expansion was 4.8%. Japan’s return was 8.6% while earnings growth was 7.8% and the valuation metric declined by 1.4%. Emerging markets return was 5.6% while earnings growth was 0.1% and valuation expansion was 2.7%. China’s return was 7.1% while earnings growth was 0.2% and valuation expansion was 4.2%.

Sources: FactSet, MSCI. "Earnings growth" represents the annualized 10-year growth in earnings per share. "P/E expansion" represents the annualized 10-year change in trailing price-to-earnings ratios. Returns include dividends and are net of withholding taxes. All figures reflect USD. USA is represented by the MSCI USA Index, Europe is represented by the MSCI Europe Index, Japan is represented by the MSCI Japan Index, EM is represented by the MSCI Emerging Markets Index and China is represented by the MSCI China Index. As of 12/31/21.

Other markets have been growing at only about half the pace of the U.S. Europe had almost no earnings growth at all. Japan hasn't had any valuation expansion, but it’s had decent earnings growth. So those two markets have been compounding around 8% a year. Emerging markets are even lower — and a big piece of that is China, which is important to break out separately.


Until recently, Chinese markets were growing at a similar pace to the U.S., but because of recent government announcements around common prosperity and state intervention in various industries, the valuation metric has been cut roughly in half. In addition, earnings growth in China has been relatively modest. There are some fast-growing companies, but there are also lots of others in the property and banking sector that have lost money, and therefore net earnings growth has been essentially flat.


So when we look at growth around the world, most of it is finding its way to the bottom line in the U.S., which is why this market has outpaced others over the past decade. While we are seeing some excesses, what's happening in the U.S. is unique and keeps us focused on opportunities in this market. At the same time, the lack of valuation expansion across Japanese companies warrants further analysis. And while European and Chinese markets have been driven purely by valuation expansion, underneath the headline benchmarks we are finding many interesting companies at reasonable valuations. As mentioned before, it pays to focus on companies rather than markets and to look for opportunity regardless of a company’s domicile.


What are the risks that could bring this long bull market to an end?


There have been some great investors here at Capital Group, and I've learned a lot from them over the years. The primary thing they taught me was that you don't have to figure out what's going to start the fire, you just need to know the brush is dry. When you think about how the markets are currently structured, how far they've gone up and where multiples are, you just have less room for mistakes.


It’s also important to note that some of the excesses today aren’t necessarily in listed securities, but in the private equity markets and so-called PIPE (private investment in public equity) deals. That's where I’m seeing things that worry me, and that's why I am in no way sending a panic signal about the public equity markets. As we’ve just demonstrated, U.S. stocks are driven as much by earnings expansion as P/E expansion, and that's healthier than I think most people realize.


What’s your view on China, given the new regulatory environment?


The two biggest investment decisions we have to get right revolve around the U.S. and China. The U.S. is the largest market and economy in the world. China is now the second largest economy. The key issue right now is — and this oddly came as a surprise to some investors — China is a socialist country. During the past year, the government has reasserted control over a number of industries, and that has resulted in steep valuation declines for many of the affected companies.


That’s been disappointing to some, but it doesn’t mean you shouldn’t invest in China. This is a fast-growing economy with a lot of innovation, especially in the technology and health care sectors. China has incredible tech companies that don’t exist anywhere else. And new drugs are being developed that will have a major impact on the treatment of diseases worldwide. So I wouldn’t count out China from an innovation and investment perspective. You just have to assess the situation on a company-by-company basis and adjust your price expectations accordingly.


Where else are you seeing pockets of growth and innovation?


We’ve already discussed the FAANGs and the extent to which they led the bull market. These are companies with wide moats. They’re making a lot of money — and not just in their core business areas. Some have two or three other strong pillars of growth. And while people may argue that valuations are stretched, they are less stretched than they were a few years ago because the underlying earnings are so powerful.


I am also excited about advancements in the health care industry. Most of the COVID vaccines have resulted from the mRNA technology delivery system developed about 20 years ago, and it’s finally finding its way into common drugs. This structure will be used to develop multiple new treatments and even cures for deadly diseases. It’s going to change our lives, so I’m interested in a number of companies in that space.


COVID-19 vaccines were developed at breakneck speed

The image shows a timeline of vaccine development measured in months from 1880 to 2020. The typhoid fever vaccine took 105 years to develop. The polio vaccine took 47 years. The influenza vaccine took 12 years. The measles vaccine took 10 years. The chickenpox vaccine took 42 years. The hepatitis B vaccine took 16 years. The Ebola vaccine took 42 years. And COVID-19 vaccines took less than one year.

Sources: Capital Group, NIAID, Our World in Data. Date ranges represent the approximate time between the year the pathogenic agent was first linked to the disease and the year that its vaccine became licensed in the United States.

Also, don’t count out Europe and some of the emerging markets. They've learned from the U.S. and China, and they are creating their own centers of excellence, especially in the technology sector. I see this in Canada as well. There are many companies building their own innovative platforms. They have great products that they are bringing to market in the digital and meta worlds.


How are you positioning your portfolios for the year ahead?


As a long-term investor, I have an average holding period of about eight years, so I'm trying to build an all-weather portfolio. We have this incredible bull market in the U.S., and I don’t want to count it out, so my view is: I'm buying the raincoat, but I'm not putting it on yet. I just want to have that raincoat nearby. And with low interest rates, cash isn't as attractive an asset class to use on the defensive side.

“I'm buying the raincoat, but I'm not putting it on yet.”


I’m looking more toward durable companies with strong operating positions, often dividend payers. Because of the duration of the bull market and current valuations, I am cautious and shifting where I can to strong cash-flow generating companies. But when our analysts find amazing new companies doing innovative things, I can often be convinced to hold a few in my portfolio. That's why I describe it as all-weather. It's structured with a nice core, but I try not to miss some of these opportunities, particularly in the digital space.


What’s your perspective on Environmental, Social and Governance (ESG) issues?


ESG is everywhere, and it's only going to get more important. At Capital Group, we have made a commitment to fully integrating ESG principles into our investment process. So every security now goes through an ESG filter. We're factoring that into our investment decisions because we know it's going to be driving prices and outcomes.


We have a role as bottom-up fundamental investors who are out there every day talking to companies. Companies want to do the right thing. They want better governance. They want to treat their workforce better. They want to have minimal climate impact. And they are looking to us for guidance on those issues. We understand this responsibility, so we’ve created a strong ESG core group that helps bring these issues to the forefront.


In addition, it’s important to give asset managers the flexibility to evaluate companies from an ESG perspective, rather than simply banishing some companies from a portfolio. Don't think of ESG as just an exclusion process. Think of it as identifying companies that are doing the right thing and also supporting companies in transition.


ESG concepts are global and cut across all asset classes

The image shows three text boxes with the defining aspects of Environmental, Social and Governance concepts. For Environmental, they include climate change, waste management, renewable energy, water utilization, resource efficiency and pollution externalities. For Social, they include workforce diversity, health and safety, training and development, human rights, community relations, supply chain transparency and political contributions. For Governance, they include disclosure and transparency, executive compensation, corporate board structure, ownership and control, capital allocation and shareholder rights.

Source: Capital Group.

I understand there is some trepidation about how ESG concepts will be implemented in our industry. People are worried about new government regulations, additional rules or expanded disclosure requirements. But I would say: Get over it. This is important. There's a lot to learn, but I would go into it with a sense of optimism and enthusiasm.


Any parting thoughts?


First of all, remember that even though the pandemic isn’t fading, it shouldn’t scare you. It should have less impact over time. Second, we're in the 11th year of an extended bull market and near the end of the cycle. Some type of correction is likely, but it’s not time to panic. What's happening underneath is solid, healthy and underpinned by strong earnings growth.


For all the worries about rising inflation and broken supply chains, we’re seeing lots of opportunities in individual companies and securities throughout the world. I feel pretty good about the investment landscape. I’m also proud of the way the world has handled this incredible pandemic. We found ourselves in a very tough situation, but we got creative and figured out a way to get through it.


Bottom line: Stay invested. Don’t try to time the market. We’re here to help.



Rob Lovelace is an equity portfolio manager and chair of Capital International, Inc. He has 38 years of investment industry experience (as of 12/31/2023). He holds a bachelor’s degree in mineral economics from Princeton University. He also holds the Chartered Financial Analyst® designation. 


Investing outside the United States involves risks, such as currency fluctuations, periods of illiquidity and price volatility, as more fully described in the prospectus. These risks may be heightened in connection with investments in developing countries. Small-company stocks entail additional risks, and they can fluctuate in price more than larger company stocks.


The market indexes are unmanaged and, therefore, have no expenses. Investors cannot invest directly in an index.


MSCI China Index captures large and mid cap representation across China A shares, H shares, B shares, Red chips, P chips and foreign listings (e.g., ADRs). The index covers about 85% of this China equity universe.


MSCI Emerging Markets Index is a free float-adjusted market capitalization-weighted index that is designed to measure equity market results in the global emerging markets, consisting of more than 20 emerging market country indexes.


MSCI Europe Index is a free float-adjusted market capitalization-weighted index that is designed to measure results of more than 10 developed equity markets in Europe.


MSCI Japan Index is a free float-adjusted market capitalization-weighted index that is designed to measure the equity market results of Japan.


MSCI USA Index is a free float-adjusted, market capitalization-weighted index that is designed to measure the U.S. portion of the world market.


Standard & Poor's 500 Composite Index is a market capitalization-weighted index based on the results of approximately 500 widely held common stocks.


Standard & Poor’s 500 Composite Index (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Capital Group. Copyright © 2022 S&P Dow Jones Indices LLC, a division of S&P Global, and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part is prohibited without written permission of S&P Dow Jones Indices LLC.


MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

RELATED INSIGHTS
Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.
Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and should not be considered advice, an endorsement or a recommendation.
All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies.
Use of this website is intended for U.S. residents only.
American Funds Distributors, Inc.
This content, developed by Capital Group, home of American Funds, should not be used as a primary basis for investment decisions and is not intended to serve as impartial investment or fiduciary advice.